Robust Avoidance of Edge-Localized Modes alongside Gradient Formation in the Negative Triangularity Tokamak Edge.

In a series of high performance diverted discharges on DIII-D, we demonstrate that strong negative triangularity (NT) shaping robustly suppresses all edge-localized mode (ELM) activity over a wide range of plasma conditions: ⟨n⟩=0.1-1.5×10^{20} m^{-3}, P_{aux}=0-15 MW, and |B_{t}|=1-2.2 T, corresponding to P_{loss}/P_{LH08}∼8. The full dataset is consistent with the theoretical prediction that magnetic shear in the NT edge inhibits access to ELMing H-mode regimes; all experimental pressure profiles are found to be at or below the infinite-n ballooning stability limit. Our present dataset also features edge pressure gradients in strong NT that are closer to an H-mode than a typical L-mode plasma, supporting the consideration of NT for reactor design.

Field-Line Localized Destabilization of Ballooning Modes in Three-Dimensional Tokamaks.

Field-line localized ballooning modes have been observed at the edge of high confinement mode plasmas in ASDEX Upgrade with rotating 3D perturbations induced by an externally applied n=2 error field and during a moderate level of edge localized mode mitigation. The observed ballooning modes are localized to the field lines which experience one of the two zero crossings of the radial flux surface displacement during one rotation period. The localization of the ballooning modes agrees very well with the localization of the largest growth rates from infinite-n ideal ballooning stability calculations using a realistic 3D ideal magnetohydrodynamic equilibrium. This analysis predicts a lower stability with respect to the axisymmetric case. The primary mechanism for the local lower stability is the 3D distortion of the local magnetic shear.

Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group.

BACKGROUND: In recent years, brain lymphoma incidence has dramatically increased, presumably because of elevated risk of brain lymphoma among persons with acquired immunodeficiency syndrome (AIDS). PURPOSE: The objective of this study was to estimate independent incidence and survival rates of brain lymphoma among persons with or without AIDS and to understand the epidemiologic features of this cancer. METHODS: We linked AIDS and cancer registry reports at nine state and local health departments and compared the demographics, histology, and survival of brain lymphoma cases among persons with or without AIDS. The data were limited to people under 70 years of age. We calculated the incidence of brain lymphoma among persons with AIDS and compared observed cases with those expected. The differences were statistically analyzed using the Poisson test. Epidemiologic features of brain lymphoma in persons with or without AIDS were compared using the chi-squared test, the Student's t test, and the chi-squared test for linear trend. The logrank test was used to compare survival rates estimated by the Kaplan-Meier technique. All P values were two-sided. RESULTS: We matched 50,989 AIDS registry reports to 859,398 cancer registry reports (data from 1981 to 1990) and found 431 people with both AIDS and brain lymphoma. Among people with AIDS, those developing brain lymphoma versus those without brain lymphoma were more likely to be white (70% versus 59%; P < .001) and had homosexuality as their only human immunodeficiency virus risk factor (75% versus 64%; P < .001). Of the 431 patients, 223 developed brain lymphomas during 47,465 person-years of observation after diagnosis of AIDS. The absolute incidence rate of brain lymphoma among persons with AIDS was 4.7/1000 person-years (95% confidence interval = 4.1-5.3/1000 person-years), 3600-fold higher than the base-line rate in the general population. From 1980 through 1989, overall counts of brain lymphoma increased ninefold. Most of this increase was derived from persons with AIDS, but a substantial increase also occurred among persons without AIDS (0.04/100,000 in 1982 to 0.28/100,000 in 1989) (chi-squared test for trend; P < .05). The median survival was shortest for persons with AIDS and brain lymphoma (2 months), was intermediate for persons with brain lymphoma without AIDS (5-7 months), and was longest for persons with AIDS without brain lymphoma (14 months) (P < .05 for all comparisons). CONCLUSIONS: This analysis distinguishes the separate epidemiologies of brain lymphoma incidence among persons with or without AIDS and shows brain lymphoma incidence among persons with AIDS to be several thousand-fold higher than that in the general population. The study documents the overwhelming effect of AIDS-associated brain lymphoma on the overall rate in the general population and demonstrates a significantly rising trend, although of a lesser magnitude, among persons without AIDS. IMPLICATIONS: This study emphasizes a greater need to bring health care resources to this burgeoning epidemic.

Nalpha-trinitrophenyl glucagon: an inhibitor of glucagon-stimulated cyclic AMP production and its effects on glycogenolysis.

Nalpha-Trinitrophenyl glucagon was prepared by reaction with trinitrobenzene sulfonic acid and purified by ion-exchange chromatography. This derivative has essentially no ability to activate adenylate cyclase from rat liver nor to increase the levels of cyclic AMP in isolated hepatocytes nor to stimulate protein kinase activity. This derivative also can act as a glucagon antagonist with regard to cyclic AMP production and can decrease the degree of stimulation of adenylate cyclase caused by glucagon, as well as lowering the glucagon-stimulated elevation of cyclic AMP levels in intact hepatocytes. Nevertheless, this derivative is capable of activating glycogenolysis in isolated hepatocytes and in augmenting the effect of glucagon on glycogenolysis. This metabolic effect of the glucagon derivative thus appears to occur independent of changes in cyclic AMP levels. These results suggest that glucagon can also activate glycogenolysis by a cyclic AM-independent process.

Conformational and biological properties of a covalently linked dimer of glucagon. Reaction of mono- and bifunctional sulfenyl halides.

The tryptophan residue of glucagon was modified by reaction with a mono-functional sulfenyl chloride (2-nitrophenylsulfenyl chloride) and with a bifunctional sulfenyl chloride (2,4-dinitro-1,5-phenyldisulfenyl chloride) to produce a monomeric form of glucagon with a modified tryptophan, glucagon-nitrophenylsulfenyl and a dimeric form (glucagon)2-dinitrophenyldisulfenyl respectively. The dimeric form was isolated by chromatography on Sephadex G-50. The circular dichroism spectra of pH and low temperature. The derivatives activated adenylate cyclase from rat liver to an extent comparable to that of the native hormone, indicating that a glucagon dimer is capable of biological activity and that an intact tryptophan residue is not essential for biological response.

Site of pertussis toxin-induced ADP-ribosylation on Gi is critical for receptor modulation of GDP interaction with Gi.

In this study, the influence of the inhibitory mu-opioid receptor on the potencies of 5'-guanosine alpha-thiotriphosphate (GTP gamma S) and GDP at the inhibitory GTP-binding protein (Gi) were investigated in an adenylyl cyclase system. It was hoped that a receptor-mediated change in the potency of either GTP gamma S or GDP in affecting adenylyl cyclase activity may elucidate how a receptor alters cyclase activity via its G-protein. In an adenylyl cyclase system employing 5'-adenylyl imidodiphosphate as substrate, GTP gamma S, a nonhydrolyzable analog of GTP, inhibited forskolin-stimulated adenylyl cyclase activity in the absence of morphine; morphine failed to significantly affect the apparent potency of GTP gamma S. GDP blocked the GTP gamma S-induced inhibition of adenylyl cyclase; morphine profoundly diminished the ability of GDP to block the inhibitory effect of GTP gamma S. The IC50 values of GTP gamma S were 0.02 +/- 0.01, 0.18 +/- 0.04, and 2.2 +/- 0.5 microM in the absence of other drugs, in the presence of a combination of 100 microM GDP and morphine, and in the presence of 100 microM GDP, respectively. GDP blocked the inhibitory effect of GTP gamma S (0.3 microM) in a concentration-dependent manner; the EC50 for GDP was 16 +/- 2.6 microM in the absence of morphine and 170 +/- 32 microM in the presence of morphine. Exposure of 7315c cells to pertussis toxin for 3 h resulted in a small decrease in the potency of GTP gamma S in inhibiting cyclase. However, the relative potency of GDP in blocking the GTP gamma S-mediated inhibition of cyclase was increased: the EC50 values of GDP were 11 +/- 4 and 0.81 +/- 0.2 microM in untreated and pertussis toxin-treated membranes, respectively. In untreated membranes, there was a brief lag in the GTP gamma S-induced inhibition of adenylyl cyclase; morphine diminished this lag. In membranes treated with pertussis toxin, there was an exaggerated lag in the onset of GTP gamma S inhibition of adenylyl cyclase activity; morphine could no longer affect this lag. Thus, uncoupling the mu-opioid receptor from Gi appeared to increase the affinity of Gi for GDP. These data suggest that the effect of an inhibitory receptor is to decrease the affinity of Gi for GDP by virtue of its interaction with the carboxy-terminal region of Gi alpha.(ABSTRACT TRUNCATED AT 400 WORDS)

A systematic consideration of the neoplastic spectrum of AIDS: registry linkage in Illinois.

To examine unexplored aspects of the association between AIDS and neoplasia, the Illinois AIDS and Cancer Registries were linked. The method integrated use of a personal computer to find exact matches on names and dates of birth with manual review to assure satisfaction of a match definition. Of the factors examined, white race and homosexuality predicted Kaposi's sarcoma (KS) among people with AIDS (PWAs), and white race predicted non-Hodgkin's lymphoma (NHL). Earlier reports of a declining proportion of PWAs with KS were confirmed. Lymphoma (mixed lymphocytic/histiocytic type), while not currently diagnostic of AIDS, occurred more frequently among PWAs than in the Illinois population. For the first time, rates of cancers other than KS and NHL were demonstrated to be significantly increased among PWAs compared with general populations. In the light of these findings, reconsideration of current neoplastic definitions may be useful.

Effect of ACTH and histamine stress on serum corticosterone and adrenal cyclic AMP levels in immature rats.

Adrenal cAMP and plasma corticosterone levels were determined in pre-weanling rats subjected to treatment with either ACTH (50 mU/rat) or histamine dihydrochloride (0.2 mg/g body wt). ACTH injection elevated both serum corticosterone and adrenal cAMP levels on all days tested. However, the ACTH-induced elevation of adrenal cAMP and serum corticosterone both diminished steadily from day 2 to day 8 and then increased from day 8 to day 16. Histamine injection resulted in elevated serum corticosterone levels in a pattern similar to that of the corticosterone response to ACTH. However, histamine injection did not result in any significant increase in adrenal cAMP from day 2 to day 10. From day 12 to day 16 the adrenal cAMP concentration rose steadily in parallel with ther serum corticosterone levels. These results indicate: (1) that a functional, ACTH-sensitive adenyl cyclase system is present in the adrenal gland of the immature rat, (2) that the responsiveness of this system diminishes during the first postnatal week before returning to its previous 2-day-old capacity by day 16, and (3) that during the first few days after birth, histamine stress results in elevated serum corticosterone levels without elevating adrenal cAMP levels.

Stimulation of a D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland decreases the responsiveness of the beta-adrenoceptor: biochemical mechanism.

In experiments using a cell-free homogenate of the intermediate lobe of the hypophysis of the rat, apomorphine, a dopaminergic agonist, diminished both basal and L-isoproterenol-stimulated adenylate cyclase activity; dopaminergic antagonists from several chemical families reversed these inhibitory effects of apomorphine. Apomorphine diminished the ability of GTP to enhance both basal and L-isoproterenol-stimulated adenylate cyclase activity but did not directly interfere with the interaction between the beta-adrenoceptor and L-isoproterenol. The affinity of the D-2 dopamine receptor in the intermediate lobe for each dopaminergic antagonist used in this study was estimated from a mathematical analysis of the data. (Endocrinology 108: 420, 1981)

Biochemical identification of the beta-adrenoceptor and evidence for the involvement of an adenosine 3',5'-monophosphate system in the beta-adrenergically induced release of alph-melanocyte-stimulating hormone in the intermediate lobe of the rat pituitary gland.

The beta-adrenoceptor in the intermediate lobe (IL) of the hypophysis of the rat is characterized on the basis of the following: 1) the ability of beta-adrenergic agonists to increase adenylate cyclase activity in homogenates of the IL, and 2) the ability of drugs active upon the beta-adrenoceptor to compete with [125I]hydroxybenzylpindolol, a radiolabeled beta-adrenergic antagonist, for high affinity (Kd = 232 pM) binding sites. The values of the affinity of the beta-adrenoceptor for drugs obtained in either assay system are in good agreement. The relative potency among agonists, L-isoproterenol greater than L-epinephrine greater than L-norepinephrine, suggests that the receptor is of the beta-2 subcategory. cAMP, derivatives of cAMP, and a phosphodiesterase inhibitor, theophylline, mimic the ability of l-isoproterenol to enhance the release of alpha MSH from dispersed cells of the rat IL. The present results are in accord with the possibility that occupancy by agonists of the beta-adrenoceptor of the IL enhances adenylate cyclase activity, resulting in an accumulation of cAMP which initiates the intracellular events that are ultimately expressed as an enhanced release of alpha MSH. Pharmacological data suggest that stimulation of a dopamine receptor in the IL diminishes the response of the beta-adrenoceptor to agonists.

Guanyl nucleotides participate in the beta-adrenergic stimulation of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.

The existence of a stimulatory guanyl nucleotide component in the intermediate lobe of the rat pituitary gland (IL) is supported by the observations that: 1) GTP was required for beta-adrenergic stimulation of adenylate cyclase activity in homogenates of IL tissue; 2) GTP, in the absence of a beta-adrenergic agonist, maximally stimulated adenylate cyclase activity in homogenates of IL tissue previously treated with cholera toxin; and 3) GTP decreased the affinity of the beta-adrenoceptor for isoproterenol, a beta-adrenergic agonist. Although when tested on fresh IL tissue, 5'-guanylyl imidodiphosphate [Gpp(NH)p], a nonhydrolyzable analog of GTP, was substantially less active than GTP in stimulating adenylate cyclase activity in the presence of isoproterenol, GTP and Gpp(NH)p each stimulated adenylate cyclase to the same degree after solubilization of IL tissue previously treated with cholera toxin. GTP and Gpp(NH)p appeared to interact at the same site in this preparation.

The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization.

The dopamine receptor in the intermediate lobe (IL) of the hypophysis of the rat is characterized on the basis of the ability of dopamine and other dopaminergic agonists to decrease the consequences of activation of the beta-adrenoceptor. Stimulation of the dopamine receptor diminishes the L-isoproterenol-induced accumulation of cAMP and the catecholamine-stimulated enhancement of adenylate cyclase activity. The dopamine receptor in the IL can be assigned to the category of dopamine receptor designated D-2 on the basis of the following criteria: 1) occupancy of the dopamine receptor does not result in enhancement of adenylate cyclase activity or an accumulation of cAMP, 2) the dopaminergic ergots and apomorphine mimic the inhibitory effect of dopamine upon cAMP formation or alpha MSH release, and 3) metoclopramide and sulpiride, substituted benzamides, block the inhibitory effect of dopamine. The sympathetic neurotransmitter, norepinephrine, interacts with the dopamine receptor and the beta-adrenoceptor in the IL.

Coordinated action of calcium ion and adenosine 3',5'-monophosphate upon the release of alpha-melanocyte-stimulating hormone from the intermediate lobe of the rat pituitary gland.

Stimulation of the release of alpha MSH from dispersed rat melanotrophs by L-isoproterenol, 8-bromo-cAMP, or cholera toxin requires calcium ion (Ca++) in the incubation medium; the stimulatory effect of each of these agents is attenuated by D-600, a Ca++ antagonist. In contrast, stimulation of the formation of cAMP by L-isoproterenol, isobutyl methylxanthine, or cholera toxin does not require Ca++ in the incubation medium. Ca++ diminishes the amount of cAMP formed by cholera toxin-treated melanotrophs. Ca++ inhibits adenylate cyclase activity and enhances cyclic nucleotide phosphodiesterase activity in cell-free homogenates of intermediate lobe tissue. A23187, a calcium ionophore, increases the accumulation of 45Ca by melanotrophs and enhances the release of alpha MSH. Furthermore, when tested upon cholera toxin-treated melanotrophs, A23187 potentiates the Ca++-induced inhibition of cAMP formation. The results indicate that Ca++ is essential for the release of alpha MSH, and that cAMP in some way enhances the effects of Ca++ upon the release process.

[3H]spiroperidol identifies a D-2 dopamine receptor inhibiting adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.

[3H]Spiroperidol ([3H]SPIRO) binds with high affinity (Kd = 0.3 nM) to cell-free homogenates of the neurointermediate lobe of the rat pituitary gland. The neurointermediate lobe contains 19.2 fmol of specific binding sites, 86% of which occur in the intermediate lobe (IL). Compounds active upon the D-2 dopamine receptor in the IL compete with [3H]SPIRO for occupancy of the specific binding site. Guanosine 5'-triphosphate decreases the affinity of agonists, but not antagonists, for the specific binding site. For each drug tested, methods derived from competitive enzyme kinetics were used to calculate the apparent affinity constants of the drug for the binding site and for the receptor regulating adenylate cyclase activity. The pharmacological properties of the specific [3H]SPIRO binding site were compared to the pharmacological properties of the D-2 dopamine receptor inhibiting adenylate cyclase activity in the IL. The similarity between the affinities determined from the binding and enzyme assays suggests that some or all of the specific [3H]SPIRO binding sites in the IL are D-2 dopamine receptors inhibiting adenylate cyclase activity.

D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5'-triphosphate.

After treatment with cholera toxin, homogenates of intact intermediate lobe (IL) tissue of rat pituitary gland synthesized more cAMP than did homogenates of untreated IL tissue, and only in the presence of GTP did dopamine or apomorphine diminish the elevated adenylate cyclase activity in homogenates of cholera toxin-treated IL tissue. Furthermore, when tested on cholera toxin-treated IL tissue, 5'-guanylyl imidodiphosphate [Gpp(NH)p] and two other nonhydrolyzable analogs of GTP inhibited adenylate cyclase activity in the absence of either a dopaminergic agonist or GTP; GTP reversed the Gpp(NH)p-induced inhibition of adenylate cyclase activity. Apomorphine, a dopaminergic agonist, abolished the ability of GTP to reverse the inhibition by Gpp(NH)p; this effect of apomorphine was prevented by fluphenazine, a dopaminergic antagonist. Sodium fluoride inhibited adenylate cyclase activity to approximately the same level obtained with GTP and apomorphine. In addition, apomorphine decreased cAMP accumulation and alpha MSH release from dispersed IL cells pretreated with cholera toxin.

Bromocriptine-induced changes in the biochemistry, physiology, and histology of the intermediate lobe of the rat pituitary gland.

Treatment of rats with 2-Br-alpha-ergocryptine (bromocriptine; CB 154) elicits biochemical, physiological, and histological changes in the intermediate lobe (IL) of the rat pituitary gland, suggesting a decrease in activity in the IL. CB 154 treatment decreases 1) the capacity of the IL to synthesize proopiomelanocortin (POMC), 2) the content of mRNA directing the synthesis of POMC, and 3) the capacity of the IL to synthesize the peptides desacetyl alpha MSH, N,O-diacetyl alpha MSH, and alpha MSH. CB 154 treatment also causes a 40% loss of IL protein and an atrophy of the IL. CB 154 treatment has a biphasic effect upon the IL content of alpha MSH-like peptides; the drug first increases and then diminishes the content of these molecules. Control experiments using CB 154-treated IL tissue suggest that these effects of CB 154 are not a toxic effect of CB 154 on the IL. Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH. Stalk section of rat pituitary gland also results in an increase in the capacity of the IL to synthesize POMC. These results suggest that a D-2 dopamine receptor mediates a tonic inhibition of the function of the IL.

Muscarinic depression of synaptic transmission and blockade of norepinephrine-induced long-lasting potentiation in the dentate gyrus.

Bath application of the muscarinic receptor agonist, muscarine, produced a concentration-dependent depression of synaptic activity in the dentate gyrus of hippocampal slices. A concentration of 10 microM muscarine produced a reversible depression that could be competitively antagonized by the muscarinic receptor antagonist pirenzepine. However, other muscarinic receptor subtype (M1-M3) antagonists could also block the effects of muscarine. The rank order of antagonist potency was: 4-diphenylacetoxy-N-methyl-piperidine methiodide (M3/M1 antagonist) > pirenzepine (M1) > AFDX-116 (M2). The depression produced by 10 microM muscarine was not affected by in vivo pretreatment with pertussis toxin, and therefore was not mediated by a pertussis toxin-sensitive G-protein. In addition, high concentrations of muscarine did not affect either basal or isoproterenol-stimulated accumulation of cyclic AMP from slices of dentate gyrus. Muscarine also produced a concentration-dependent blockade of the induction of norepinephrine-induced long-lasting potentiation in the dentate gyrus. Norepinephrine-induced long-lasting potentiation is a form of long-lasting plasticity induced in medial perforant path synapses by beta-adrenergic agonists such as isoproterenol. The muscarinic blockade of norepinephrine-induced long-lasting potentiation was also prevented by pretreatment with pirenzepine. Based on these pharmacological data, we conclude that muscarinic depression of evoked responses, as well as blockade of norepinephrine-induced long-lasting potentiation, involves activation of either M3 or M1, but not M2, muscarinic receptors. These data also demonstrate that in addition to modulating normal synaptic transmission, muscarinic receptors may also play an important role in modulating synaptic plasticity.

Bicycle helmet use among Maryland children: effect of legislation and education.

Although bicycle helmets are effective in preventing head injuries, use of helmets among children remains infrequent. In response to the bicycling deaths of two children, Howard County, Maryland, became the first US jurisdiction to mandate use of bicycle helmets for children. Schoolchildren were lectured by police about the law before its enactment. Prelaw and postlaw helmet use was observed in Howard County and two control counties: Montgomery (which sponsored a community education program) and Baltimore County (no helmet activities). Prelaw crude helmet use rates for children were 4% (95% confidence interval [CI] 0% to 10%) for Howard, 8% (95% CI 3% to 13%) for Montgomery, and 19% (95% CI 5% to 33%) for Baltimore. Postlaw rates were 47% (95% CI 32% to 62%), 19% (95% CI 11% to 27%), and 4% (95% CI 0 to 11%), respectively. The rate of bicycle helmet use by Howard County children is now the highest documented for US children. A similar increase in helmet use among children younger than 16 years nationwide could prevent about 100 deaths and 56,000 emergency-department-treated head injuries annually. Physicians and other health professionals should consider proposing and supporting the Howard County approach in their communities.

Chronic obstructive pulmonary disease mortality. A role for altitude.

A map of US COPD mortality rates by state suggested that the relative hypoxia of increased altitude may be independently associated with COPD mortality. This was investigated using linear regression analysis of 1986 state-specific data on COPD mortality rates, history of cigarette consumption, and altitude. County seat altitudes and county populations were used to calculate the median altitude of state residents. We found independent significant associations between COPD and both smoking and altitude. State COPD mortality rose by 1/10(5) for every 5.4 increase in mean packs consumed per capita per year or for each 95-m increase in resident altitude. There was no association between altitude and smoking. If increased altitude does contribute to COPD mortality, persons with this disease may benefit from down-migration.

Desensitization of the D-2 dopamine receptor and the ?(2)-adrenoceptor in the intermediate lobe of the rat pituitary gland.

A D-2 dopamine receptor and a ?(2)-adrenoceptor occur in the intermediate lobe of the rat pituitary gland (IL). Exposure of intact IL tissue to a D-2 agonist diminished the ability of dopaminergic agonists [but not 5?-guanylyl imidodiphosphate (Gpp(NH)p)] to inhibit adenylate cyclase activity. Conversely, exposure of intact IL tissue to a ?-adrenergic agonist diminished the ability of a ?-adrenergic agonist (but not forskolin) to stimulate adenylate cyclase activity. Treatment of ovariectomized rats with 17?-estradiol desensitizes the ?(2)-adrenoceptor but not the D-2 receptor. Desensitization of the IL catecholamine receptors is discussed within the framework of a previously published "working model" of these receptors.